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Abstract
 
Human thymic stromal lymphopoietin (TSLP) is a novel epithelial cell–derived cytokine,
which induces dendritic cell (DC)-mediated CD4
 
 
 
 T cell responses with a proallergic pheno-
type. Although the participation of CD8
 
 
 
 T cells in allergic inflammation is well docu-
mented, their functional properties as well as the pathways leading to their generation remain
poorly understood. Here, we show that TSLP-activated CD11c
 
 
 
 DCs potently activate and
expand naive CD8
 
 
 
 T cells, and induce their differentiation into interleukin (IL)-5 and IL-13–
producing effectors exhibiting poor cytolytic activity. Additional CD40L triggering of
 
TSLP-activated DCs induced CD8
 
 
 
 T cells with potent cytolytic activity, producing large
 
amounts of interferon (IFN)-
 
 
 
, while retaining their capacity to produce IL-5 and IL-13.
These data further support the role of TSLP as initial trigger of allergic T cell responses and
suggest that CD40L-expressing cells may act in combination with TSLP to amplify and sus-
tain pro-allergic responses and cause tissue damage by promoting the generation of IFN-
 
 
 
–
producing cytotoxic effectors.
Key words: TSLP • CD11c
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Introduction
 
Thymic stromal lymphopoietin (TSLP) is a novel IL-7–like
cytokine, cloned from a murine thymic stromal cell line
(1). While mouse TSLP supports early B and T cell devel-
opment, human TSLP (hTSLP) only activates CD11c
 
 
 
dendritic cells (DCs), but not other antigen presenting
cells, B, T, NK cells, neutrophils, nor mast cells (2, 3). This
is in accordance with the coexpression of mRNA for the
IL-7R
 
 
 
 chain and TSLPR by CD11c
 
 
 
 DCs but not other
cell types (2). Unlike most DC activators such as CD40-
ligand and ligands for Toll-like receptors (LPS, CPG-
DNA, poly I:C), hTSLP does not induce DCs to produce
 
proinflammatory cytokines (IL-1, IL-6, TNF-
 
 
 
, and IL-12),
but TH2-attracting chemokines TARC and MDC (3). In-
terestingly, hTSLP-activated DCs prime CD4
 
 
 
 T helper
cells to produce proallergic cytokines IL-4, IL-5, IL-13,
and TNF-
 
 
 
, while down-regulating IL-10 and IFN-
 
 
 
.
hTSLP is highly expressed by epithelial cells of inflamed
tonsils and keratinocytes of atopic dermatitis and its expres-
sion is associated with Langerhans cell migration and acti-
vation (3). hTSLP represents the first epithelial cell–derived
cytokine that directly triggers DC-mediated TH2 allergic
inflammation.
Allergic inflammation is the result of a complex immu-
nological cascade involving the production of TH2 cyto-
kines IL-4, IL-5, and IL-13, which leads to eosinophilia
and IgE-production by B cells (4, 5). The production of
these proallergic TH2 cytokines was initially ascribed to
CD4
 
 
 
 T cells (6, 7). There is now broader evidence that
CD8
 
 
 
 T cells, once regarded solely as potent cytotoxic
effectors in antiviral and antitumoral immunity, are also
able to secrete TH2 cytokines (8–10). Substantial numbers
of CD8
 
 
 
 T cells participate in allergic inflammation (11,
12). However, the functional properties of such CD8
 
 
 
 T
cells as well as the pathways leading to their generation re-
main poorly understood.
In this study we demonstrate that human TSLP primes
 
DCs to induce naive CD8
 
 
 
 T cell activation and differen-
tiation into IL-5– and IL-13–producing T cells. Addi-
tional CD40 ligand stimulation of TSLP-DCs induced the
differentiation of CD8
 
 
 
 T cells into effectors that exhibit
potent cytolytic activity and produce large amounts of
 
IFN-
 
 
 
, in addition to IL-5 and IL-13, two types of cyto-
kines that were considered to be mutually exclusive (13).
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Our data suggest that TSLP-activated DCs play an impor-
tant role in inducing both CD4
 
 
 
 and CD8
 
 
 
 T cell–medi-
ated allergic inflammation.
 
Materials and Methods
 
DC Purification and Culture.
 
CD11c
 
 
 
 DCs were purified
from buffy coats of HLA-A2–positive volunteer blood donors
after separation of PBMCs by Ficoll-Hypaque centrifugation
(Amersham Biosciences) and immunomagnetic depletion us-
ing mouse anti-CD3 (OKT3), anti-CD14 (RPA-M1), anti-
CD19 (Leu-12), anti-CD56 (Leu-19), and anti-glycophorin-A
(10F7MN) followed by magnetic beads coated with goat anti–
mouse IgG (Dynabeads M-450; Dynal). Depleted cells were fur-
ther stained with PE-Cy5–conjugated anti-CD4 (Caltag), PE-
conjugated anti-CD11c and FITC-conjugated anti-CD3, CD14,
CD16, and CD20 (all Becton Dickinson). FITC
 
 
 
CD11c
 
 
 
 DCs
were isolated with a Vantage FACsorter™ (Becton Dickinson) to
reach a purity 
 
 
 
99% .
CD11c
 
 
 
 DCs were cultured immediately after sorting in
RPMI containing 10% FCS, 1% pyruvate, 1% HEPES, and peni-
cillin-streptomycin. Cells were seeded at 0.5 
 
 
 
 10
 
6
 
/ml in flat-
bottomed 96-well plates in the presence of medium alone, TSLP
(15 ng/ml), CD40L-transfected L fibroblasts (2.5 
 
 
 
 10
 
4
 
/well), or
a combination of TSLP and CD40L-transfected L fibroblasts.
DCs were harvested after 24 h of culture and stained with FITC-
labeled anti-CD80 and anti-CD86 (Becton Dickinson) to assess
their state of maturation.
 
Isolation of Naive CD8
 
 
 
 T Lymphocytes from Adult Blood.
 
Na-
ive CD8
 
 
 
 T cells were enriched from PBMCs of HLA-A2–nega-
tive healthy donors by immunomagnetic depletion using a cock-
tail of mouse anti-CD4, anti-CD14, anti-CD16, anti-CD19,
anti-HLA-DR, and anti-CD45RO mAb, followed by magnetic
beads coated with goat anti–mouse IgG. These cells were stained
with PE-Cy5–conjugated anti-CD45RA, PE-conjugated anti-
CD27 (both BD Biosciences), and a cocktail of FITC-conjugated
anti-CD4, anti-
 
  
 
TCR, anti-CD14, anti-CD16, and anti-CD20
mAbs (Becton Dickinson). CD27
 
 
 
CD45RA
 
 
 
lineage
 
 
 
 cells were
isolated by fluorescence activated cell sorting and were 
 
 
 
98%
CD8
 
 
 
 T cells. CD8
 
 
 
CD27
 
 
 
CD45RA
 
 
 
 have been previously
described as naive CD8
 
 
 
 T cells.
 
DC/CD8 T Cell Cocultures.
 
CD11c
 
 
 
 DCs were collected af-
ter 24 h of culture under different conditions, washed twice to
remove any residual cytokine, and cultured with 5 
 
 
 
 10
 
4
 
 freshly
isolated naive CD8
 
 
 
 T cells in round-bottomed 96-well plates at
a ratio of 1:5 DC:T cell. After 6 d, cultures were harvested and
numbers of viable cells determined by trypan blue exclusion.
 
Analysis of Cytokine Production.
 
To test their capacity to se-
crete cytokines, harvested CD8
 
 
 
 T cells (10
 
6
 
/ml) were restimu-
lated with plate-bound anti-CD3 mAb (10 
 
 
 
g/ml) plus 1 
 
 
 
g/ml
soluble anti-CD28 mAb for 24 h. IFN-
 
 
 
, TNF-
 
 
 
, IL-4, IL-5,
IL-13, and IL-10 in the culture supernatants were measured by
Quantikine ELISA kits (R&D Systems).
 
Cytotoxicity Assay and Intracellular Perforin Expression.
 
Har-
vested CD8
 
 
 
 T cells were tested for the capacity to lyse 
 
51
 
Cr-
labeled HLA-A2–positive EBV-B lymphoblastoid cell line JY.
The HLA-A2–negative EBV-LCL RSB cell line (DNAX) was
used as negative control target. The assay was performed by in-
cubating 2,500 
 
51
 
Cr-labeled target cells per well with indicated
numbers of effectors at 37
 
 
 
C for 5 h before collecting the super-
natants and measuring 
 
51
 
Cr release with a gamma counter. We
used Triton X to determine the maximum lysis, and target cells
 
alone to determine the spontaneous lysis. The percentage lysis
was calculated as follows: (spontaneous cpm 
 
 
 
 experimental
cpm)/spontaneous cpm. For quantification of perforin expression
by CD8 T cells, harvested cells were stained with PE-labeled
anti-CD8, fixed with 2% formaldehyde (Sigma-Aldrich), and
permeabilized with PBS supplemented with 2% FCS, 0.1%
NaN3, and 0.5% saponin (Sigma-Aldrich). Cells were then
stained with FITC-labeled anti-perforin mAb (for 20 min) and
analyzed on a FACScan™ flow cytometer.
 
Results
 
TSLP-DCs Induce Strong CD8
 
 
 
 T Cell Expansion.
 
The
capacity of DCs cultured with human TSLP (TSLP-DC) to
activate and differentiate naive CD8
 
 
 
 T cells was deter-
mined in comparison to DCs cultured either with medium
alone, CD40L (CD40L-DC), or with a combination of
TSLP and CD40L (CD40L
 
 
 
TSLP-DC). Whereas DCs
cultured with medium alone did not induce significant
CD8
 
 
 
 T cell expansion, CD40L-DCs induced a 1.4 to
2.8-fold expansion of CD8
 
 
 
 T cells after 6 d of coculture
(Fig. 1 A). TSLP-DCs induced a 2.8 to 5.6-fold increase in
CD8
 
 
 
 T cell number, which was 2 times more than that
induced by CD40L-DCs (Fig. 1 A). CD40L and TSLP had
a strong synergistic effect in activating DCs, as shown by
the very high levels of CD80 and CD86 expression (Fig. 1
B), and the ability to induce the strongest CD8
 
 
 
 T cell ex-
pansion (4.5 to 8.2-fold). Thus, TSLP, either alone or in
combination with CD40L, represents a very potent DC ac-
tivation factor with a marked capacity to induce DC-medi-
ated activation and expansion of naive CD8
 
 
 
 T cells.
 
TSLP-DCs Prime CD8
 
 
 
 T Cells to Produce Large Amounts
of IL-5 and IL-13.
 
To determine the capacity of TSLP-
DCs to polarize naive CD8
 
 
 
 T cells into cytokine-produc-
ing cells, DC-primed CD8
 
 
 
 T cells were restimulated for
24 h with anti-CD3 and anti-CD28 and cytokine produc-
tion was measured in the culture supernatant by ELISA
(Fig. 2). CD8
 
 
 
 T cells primed with medium-DCs pro-
duced low levels of IFN-
 
 
 
 and TNF-
 
 
 
, and did not pro-
duce detectable amounts of IL-4, IL-5, or IL-10. CD8
 
 
 
 T
cells primed with CD40L-DCs produced large amounts of
IFN-
 
 
 
 and TNF-
 
 
 
, low amounts of IL-5 and undetectable
amounts of IL-13, IL-4, or IL-10. Interestingly, CD8
 
 
 
 T
cells primed by TSLP-DCs produced large amounts of IL-5
(up to 350 pg/ml) and IL-13 (up to 170 pg/ml), and mod-
erate amounts of IFN-
 
 
 
 and TNF-
 
 
 
, but did not produce
detectable amounts of IL-4 and IL-10. DCs activated by
TSLP together with CD40L primed CD8
 
 
 
 T cells to pro-
duce the highest levels of IL-5, IL-13, TNF-
 
 
 
, and IFN-
 
 
 
,
but undetectable amounts of IL-4 and IL-10.
 
TSLP-DC Activated in the Presence of CD40L Induce
Highly Cytotoxic CD8
 
 
 
 T Cells and Secrete IL-5, IL-13, and
IFN-
 
 
 
.
 
Next, we asked whether these polarized effector
CD8
 
 
 
 T cells had characteristics of cytotoxic T cells and
could kill allogeneic targets (Fig. 3 A). DCs cultured for
24h in medium alone did not induce cytotoxic CD8
 
 
 
 T
cell activity (cytolytic activity was not significantly different
from cytolytic activity against autologous targets). Low lev-T
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els of cytotoxic activity were detected in both CD8
 
 
 
 T
cells primed with CD40L-DC or TSLP-DCs (cytolytic ac-
tivity detectable at the lowest ratio of 15 effector to 1 target
cell). In contrast, CD40L-TSLP-DCs induced very potent
of CD8
 
 
 
 cytotoxic T cells, detectable at ratios as low as 1
effector to 1 target (Fig. 3 A). The cytotoxic activity corre-
lated with the intracellular perforin expression (Fig. 3 B).
 
Discussion
 
In this study, we report that DCs activated by TSLP
have a marked ability to expand naive CD8
 
 
 
 T cells and
induce their differentiation into IL-5 and IL-13 secreting
CD8
 
 
 
 T cells. Furthermore, we show that the addition of
CD40L to the TSLP-mediated DC activation induced
CD8
 
 
 
 T cell differentiation into potent cytolytic effectors
secreting high levels of IFN-
 
 
 
, while retaining their ability
to produce high levels of IL-5 and IL-13.
The importance of CD8
 
 
 
 T cells in the pathogenesis and
exacerbation of allergic diseases has been recently high-
lighted by the identification of allergen-specific CD8
 
 
 
 T
cells (14). In addition, large numbers of CD8
 
 
 
 T cells se-
creting IL-5 and IL-13 have been observed in the inflamma-
tory infiltrate of allergic asthma (15) and atopic dermatitis
(12) as well as in the blood of patients with drug allergies
(16). CD8
 
 
 
 T cell–derived IL-5 and IL-13 were shown to
exert their proallergic functions by inducing eosinophilia
and increased IgE production, both in-vitro and in-vivo (12,
Figure 1. CD11c  DCs activated by TSLP alone or in combination with CD40L induce a strongly expansion of naive CD8  T cells. (A) Naive CD8 
T cells were cultured for 6 d with CD11c  DCs activated for 24 h with medium, CD40L, TSLP, or TSLP   CD40. TSLP-DCs induced stronger ex-
pansion of naive CD8  T cells than CD40-L-DCs. The combination of TSLP and CD40L showed an additive effect on the capacity of activated DCs to
induce CD8  T cell expansion. Data represent five independent experiments; horizontal bars represent the median value. (B) Surface expression of CD80
and CD86 by medium-DCs, CD40L-DCs, TSLP-DCs, and TSLP CD40L-DCs. TSLP-DCs showed significantly higher levels of CD80 than CD40L-
DCs, TSLP CD40L-DCs showed the highest levels of both CD80 and CD86. Filled histograms represent staining of costimulatory molecules CD80
and CD86; open histograms represent the isotype control. Numbers indicate the mean fluorescence intensity.
Figure 2. TSLP-activated
DCs induce IL-5 and IL-13–
producing CD8  T cells. Cyto-
kine production by naive CD8 
T cells primed for 6 d with me-
dium-DCs, CD40L-DCs, TSLP-
DCs, or TSLP CD40L-DCs.
Harvested CD8  T cells were
restimulated for 24 h with anti-
CD3 and anti-CD28 and IFN- ,
TNF- , IL-4, IL-5, IL-10, and
IL-13 were measured in the cul-
ture supernatant by ELISA.
TSLP-DCs and TSLP CD40L-
DCs both induced IL-5 and IL-13
producing CD8  T cells. How-
ever, in contrast to TSLP-DCs,
TSLP CD40L-DCs primed
CD8  T effector cells to pro-
duce high levels of IFN- . Data
represent one of three indepen-
dent experiments.T
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17). Interestingly, IL-10, a cytokine also produced by Th2
clones, was shown to be decreased in allergic diseases (14,
18), and can suppress allergic inflammation (19, 20). In our
study, CD8  T cells induced by TSLP-activated DCs pro-
duced high levels of IL-5 and IL-13, but low levels of IL-10,
thus exhibiting a typical proallergic cytokine profile. This
parallels our data on CD4  T cells, which can be instructed
to produce high levels of proallergic cytokines but low levels
of IL-10, when cultured with TSLP-activated DCs (3).
Allergic inflammation typically develops in two phases
with a switch from the initial type 2 cytokine profile in
acute lesions to increasing levels of IFN-  and high num-
bers of cytolytic effectors in chronic lesions, while proaller-
gic type 2 cytokines still remain at high levels (21–23). In
atopic dermatitis, both the increased IFN-  production as
well as the presence of high numbers of cytotoxic T cells
represent key pathogenic factors leading to epidermal injury
and the formation of the eczematous lesion (24, 25). In al-
lergic asthma, CD8  T cell–derived IFN-  has been linked
to bronchial hyperresponsiveness (26, 27) and the number
of lesional cytotoxic CD8  T cells have been associated
with the severity of the disease (28). Our data suggest that
TSLP may represent the initial trigger of allergic inflamma-
tion, by instructing DCs to induce IL-5 and IL-13 produc-
tion by CD8  T cells. In a second step, CD40L triggering
of TSLP-activated DCs could induce IFN-  production
and high cytotoxicity by CD8  T cells, which would have
characteristics of pathogenic T cells of the late phases of al-
lergy. These IL-5, IL-13, and IFN- –producing cytolytic
effectors might act to amplify and sustain the proallergic re-
sponse, and to cause tissue damage. In this two-step process,
an important question is the source of CD40L, in vivo. It is
generally accepted that CD40L stimulation essentially
comes from activated CD4  T cells within secondary lym-
phoid organs, during the DC–T cell cross-talk (29). How-
ever, a number of CD40L-expressing cells are recruited to
the site of allergic inflammation and could deliver a CD40
trigger to the TSLP-activated DCs, in situ. These include
Ag-specific T helper cells, but also eosinophils and baso-
phils, which express significant levels of CD40L (30).
Our study provides further evidence that human TSLP
might represent a key early mediator of allergic inflamma-
tion. The central role of TSLP, which acts upstream of
both CD4  and CD8  proallergic T cell responses, should
encourage clinical studies with specific TSLP inhibitors in
allergic diseases.
We thank J. Cupp for flow cytometry.
DNAX is supported by the Schering-Plough Corporation.
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Figure 3. CD40L-TSLP-DCs induced the generation of CD8  cytotoxic effector T cells. (A) Naive CD8  T cells were primed for 6 d with medium-
DCs (triangles), CD40L-DCs (diamonds), TSLP-DCs (circles), or TSLP CD40L-DCs (squares), collected and tested for their ability to lyse allogeneic
HLA-A2–positive target cells. Specific lysis of autologous HLA-A2–negative target cells remained below 15%. Whereas both TSLP-DCs and CD40L-
DCs induced CD8  T cells with poor cytolytic activity, TSLP CD40L-DCs induced CD8  T cells with potent cytolytic activity. Data represent one of
three independent experiments. (B) Two color staining for intracellular perforin and surface CD8 of T cells primed with medium-DCs, CD40-L-DCs,
TSLP-DCs, or TSLP CD40-L-DCs for 6 d.T
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